Table 3

IC50s for entry inhibition of replication-incompetent lentiviral vectors packaged with various envelope glycoproteins by therapeutic C peptides

C peptideIC50a (nM)
HIV-1SIVmac251VSV-G
HxB2 (X4 tropic)HxB2_T-20r(DTV) (X4 tropic)HxB2_T-20r(SIM) (X4 tropic)BaL (R5 tropic)BaL_C46r (R5 tropic)
T-201.8 ± 0.2>100>1002.5 ± 0.819.1 ± 8.9>100>100
C464.9 ± 2.16.0 ± 1.47.0 ± 1.37.6 ± 1.527.7 ± 6.8>100>100
C46-EHO1.9 ± 0.61.4 ± 0.21.2 ± 0.12.1 ± 0.84.5 ± 0.511.4 ± 2.3>100
V11.0 ± 0.32.0 ± 1.01.0 ± 0.41.1 ± 0.43.7 ± 0.810.9 ± 0.6>100
V21.2 ± 0.32.2 ± 0.81.4 ± 0.31.4 ± 0.33.3 ± 0.410.8 ± 1.4>100
V31.7 ± 0.415.8 ± 3.315.4 ± 10.82.4 ± 0.412.9 ± 2.330.3 ± 23.9>100
V41.5 ± 0.31.5 ± 0.91.4 ± 0.01.8 ± 0.46.7 ± 2.511.6 ± 3.0>100
V2o0.42 ± 0.150.26 ± 0.130.26 ± 0.120.51 ± 0.111.1 ± 0.25.0 ± 3.3>100
  • a IC50s are means ± SDs of at least two independent experiments. T-20r, T-20 resistant; C46r, reduced sensitivity to C46; VSV-G, glycoprotein of the vesicular stomatitis virus.